Headlines about Spring Bank Pharmaceuticals (NASDAQ:SBPH) have trended somewhat positive on Sunday, according to Accern. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Spring Bank Pharmaceuticals earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 44.596692839201 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern’s rankings:
- Spring Bank Pharmaceuticals (SBPH) Upgraded by ValuEngine to “Hold” (americanbankingnews.com)
- Spring Bank Pharmaceuticals Inc (SBPH) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Analysts Anticipate Spring Bank Pharmaceuticals Inc (SBPH) to Post -$0.52 EPS (americanbankingnews.com)
- Spring Bank Pharmaceuticals (SBPH) Now Covered by B. Riley (americanbankingnews.com)
- Spring Bank Pharmaceuticals’ (SBPH) Buy Rating Reaffirmed at Chardan Capital (americanbankingnews.com)
A number of equities analysts have weighed in on SBPH shares. ValuEngine raised shares of Spring Bank Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $32.00 target price (up previously from $29.00) on shares of Spring Bank Pharmaceuticals in a research note on Wednesday, February 21st. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Spring Bank Pharmaceuticals currently has an average rating of “Buy” and an average price target of $28.00.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Tuesday, February 20th. The company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.18. sell-side analysts forecast that Spring Bank Pharmaceuticals will post -2.4 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3341465/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-spring-bank-pharmaceuticals-sbph-stock-price.html.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
